Traditional approaches to growth in biopharma are no longer sustainable
pharmaphorum
AUGUST 5, 2022
Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace.
52 
Let's personalize your content